Trends in end-of-life (EOL) systemic oncologic treatment in contemporary clinical practice: insights from real-world data Published September 2021 Citation Canavan, M, Wang, X, Ascha, MS, Miksad, RA, Showalter, TN, Calip, GS, Gross, CP. . ASCO Quality Care Symposium. . https://ascopubs.org/doi/abs/10.1200/JCO.2020.39.28_suppl.253 Authors:Canavan, M, Wang, X, Ascha, MS, Miksad, RA, Showalter, TN, Calip, GS, Gross, CP Sources:ASCO Quality Care Symposium Share Posted inPublicationsTreatment patterns More publicationsBlood NeoplasiaApril 2026Real-world clinical outcomes in patients with CLL previously treated with covalent BTKi and BCL2i regimensPrescott J, Parrinello C, Sawas A, et al.Publication summaryPublicationsTreatment patternsChronic lymphocytic leukemiaISPORApril 2026Real-world (RW) treatment patterns and outcomes in patients with =2 lines of therapy (LOTS) for recurrent or progressive endometrial cancerBhak R, Iyer NN, Hopkins A, et al.Publication summaryPublicationsTreatment patternsAdvanced endometrial cancerBlood and Lymphatic Cancer: Targets and TherapyMarch 2026Health disparities in acute myeloid leukemia patients undergoing treatment with tyrosine kinase inhibitor (TKI) therapy targeting FLT3, IDH1, or IDH2Espinoza-Gutarra M, Jarrett B, Wang X, Afghahi A, Bae S. Publication summaryPublicationsHealth equityTreatment patternsAcute myeloid leukemia